Single-step detection of mutant huntingtin in animal and human tissues: A bioassay for Huntington's disease

被引:101
作者
Weiss, Andreas [1 ]
Abramowski, Dorothee [1 ]
Bibel, Miriam [1 ]
Bodner, Ruth [2 ]
Chopra, Vanita [3 ]
DiFiglia, Marian [3 ]
Fox, Jonathan [3 ]
Kegel, Kimberly [3 ]
Klein, Corinna [1 ]
Grueninger, Stephan [1 ]
Hersch, Steven [3 ]
Housman, David [2 ]
Regulier, Etienne [1 ]
Rosas, H. Diana [3 ]
Stefani, Muriel [1 ]
Zeitlin, Scott [4 ]
Bilbe, Graeme [1 ]
Paganetti, Paolo [1 ]
机构
[1] Novartis Inst BioMed Res, CH-4002 Basel, Switzerland
[2] MIT, Ctr Canc Res, Cambridge, MA 02139 USA
[3] Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Charlestown, MA 02129 USA
[4] Univ Virginia, Sch Med, Dept Neurosci, Charlottesville, VA 22908 USA
基金
美国国家卫生研究院;
关键词
Time-resolved FRET assay; Intracellular protein quantification; Disease progression; Huntington's disease; KNOCK-IN MOUSE; INCLUSION-BODY FORMATION; TRANSGENIC MICE; MODEL MOUSE; CAG REPEAT; NEUROPATHOLOGY; REVEALS; NEURONS; GENE; HD;
D O I
10.1016/j.ab.2009.08.001
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The genetic mutation causing Huntington's disease is a polyglutamine expansion in the huntingtin protein where more than 37 glutamines cause disease by formation of toxic intracellular fragments, aggregates, and cell death. Despite a clear pathogenic role for mutant huntingtin, understanding huntingtin expression during the presymptomatic phase of the disease or during disease progression has remained obscure. Central to clarifying the role in the pathomechanism of disease is the ability to easily and accurately measure mutant huntingtin in accessible human tissue samples as well as cell and animal models. Here we describe a highly sensitive time-resolved Forster resonance energy transfer (FRET) assay for quantification of soluble mutant huntingtin in brain, plasma, and cerebrospinal fluid. Surprisingly, in mice, soluble huntingtin levels decrease during disease progression, inversely correlating with brain aggregate load. Mutant huntingtin is easily detected in human brain and blood-derived fractions, providing a utility to assess mutant huntingtin expression during disease course as well as a pharmacodynamic marker for disease-modifying therapeutics targeting expression, cleavage, or degradation of mutant huntingtin. The design of the homogeneous one-step method for huntingtin detection is such that it can be easily applied to measure other proteins of interest. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:8 / 15
页数:8
相关论文
共 43 条
[1]   Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death [J].
Arrasate, M ;
Mitra, S ;
Schweitzer, ES ;
Segal, MR ;
Finkbeiner, S .
NATURE, 2004, 431 (7010) :805-810
[2]   An amyloid-forming peptide from the yeast prion Sup35 reveals a dehydrated β-sheet structure for amyloid [J].
Balbirnie, M ;
Grothe, R ;
Eisenberg, DS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (05) :2375-2380
[3]   Two-dimensional structure of β-amyloid(10-35) fibrils [J].
Benzinger, TLS ;
Gregory, DM ;
Burkoth, TS ;
Miller-Auer, H ;
Lynn, DG ;
Botto, RE ;
Meredith, SC .
BIOCHEMISTRY, 2000, 39 (12) :3491-3499
[4]   Generation of a defined and uniform population of CNS progenitors and neurons from mouse embryonic stem cells [J].
Bibel, Miriam ;
Richter, Jens ;
Lacroix, Emmanuel ;
Barde, Yves-Alain .
NATURE PROTOCOLS, 2007, 2 (05) :1034-1043
[5]   Pharmacological management of Huntington's disease: An evidence-based review [J].
Bonelli, Raphael M. ;
Wenning, Gregor K. .
CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (21) :2701-2720
[6]   Stochastic kinetics of intracellular huntingtin aggregate formation [J].
Colby, David W. ;
Cassady, John P. ;
Lin, Grace C. ;
Ingram, Vernon M. ;
Wittrup, K. Dane .
NATURE CHEMICAL BIOLOGY, 2006, 2 (06) :319-323
[7]   Fluorescence correlation spectroscopy shows that monomeric polyglutamine molecules form collapsed structures in aqueous solutions [J].
Crick, Scott L. ;
Jayaraman, Murali ;
Frieden, Carl ;
Wetzel, Ronald ;
Pappu, Rohit V. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (45) :16764-16769
[8]   Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits [J].
DiFiglia, M. ;
Sena-Esteves, M. ;
Chase, K. ;
Sapp, E. ;
Pfister, E. ;
Sass, M. ;
Yoder, J. ;
Reeves, P. ;
Pandey, R. K. ;
Rajeev, K. G. ;
Manoharan, M. ;
Sah, D. W. Y. ;
Zamore, P. D. ;
Aronin, N. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (43) :17204-17209
[9]   Trinucleotide repeats and neurodegenerative disease [J].
Everett, CM ;
Wood, NW .
BRAIN, 2004, 127 :2385-2405
[10]   A POLYMORPHIC DNA MARKER GENETICALLY LINKED TO HUNTINGTONS-DISEASE [J].
GUSELLA, JF ;
WEXLER, NS ;
CONNEALLY, PM ;
NAYLOR, SL ;
ANDERSON, MA ;
TANZI, RE ;
WATKINS, PC ;
OTTINA, K ;
WALLACE, MR ;
SAKAGUCHI, AY ;
YOUNG, AB ;
SHOULSON, I ;
BONILLA, E ;
MARTIN, JB .
NATURE, 1983, 306 (5940) :234-238